Abstract
Recent advances in mass spectrometry have skyrocketed the capabilities in translational proteomics, impacting our understanding of health and disease. Translational proteomics complements other omics disciplines (genomics, transcriptomics, and metabolomics/lipidomics), delivering new workflows that produce clinically relevant results that are quantitative and more informative. Under this new model, not only clinical profiles of patients but also their molecular profiles could be personally managed to drive for advanced treatment. However, a key challenge is to break the technical bottleneck and bridge the gap between early-stage discovery and next-stage, routine quantitative application of biomarker assays in the clinical research setting. To accelerate the discovery of clinically actionable biomarkers, we need to switch our focus from identification to quantitation. In other words, we need to achieve precision proteomics before we can achieve precision medicine. In this session, we will present examples of different commercial efforts available to achieve precision proteomics. The opening presentation will focus on how to develop success criteria for precision proteomics based on reproducibility, standardization, and scalability. The second presentation will focus on monitoring and visualizing instrument performance. The third presentation will illustrate how one can increase throughput of proteomics analysis. The last presentation will provide the targeted biomarker discovery approache based on quantitative assays.